CHEManager International’s Post

Sanofi to make €1bn biomanufacturing investment in France Sanofi France president Audrey Derveloy stated: “Throughout its history, Sanofi has always sought to equip France with the strategic platforms needed to produce the essential medicines and vaccines of today and tomorrow. This is why we chose our Vitry site to double its monoclonal antibody production capacity, after having already invested heavily in Neuville-sur-Saône to produce our future vaccines, including with mRNA technology. We have also strengthened our API [active pharmaceutical ingredients] production sites in the south of France. Our contribution to health sovereignty in Europe, and France in particular, has always been and remains unique.” - https://lnkd.in/dbQKmWvM #pharma #biopharma #biomanufacturing #vaccines #mrna #api

Sofie can support across this space with interim and consulting solutions!

Glad to have business thoughts like Hikma Pharmaceuticals I have been writing many posts about bringing new oncology medicine from china since Covid crises.. In fact one of my first recommendations was Shanghai Junshi Biosciences Co Ltd ... with a focus on its remarkable PD1 inhibitor Toripalimab.. even with FDA rejection, I discussed the reasons to be a big #opportunity here in MENA.. Still, There are selected #pharmaceutical opportunities from china or West, prescription drugs or OTC. from multinationals or #startups posted in the last 2 years here in #linkedin by myself. All of these opportunities, I can help you to get it and #efficiently execute it!.. just ask for a presentation Don't forget our industry is facing many #threats ... acting on opportunities now may balance those threats..

The COVID-19 pandemic accelerated the development of mRNA therapies, thrusting them into the spotlight. However, this breakthrough was actually the culmination of over 30 years of dedicated research. The swift arrival of vaccines can be credited to mRNA's unique modularity, which allows for highly efficient manufacturing compared to traditional biologics or viral-based vaccines. What lies ahead for the market? BioNTech founders Özlem Türeci and Ugur Sahin predict that "in 15 years, one-third of all newly approved drugs will be based on mRNA.”  Major pharmaceutical companies like Pfizer, CSL, GSK, and Sanofi are already diversifying their pipelines with mRNA-based assets. In this article, Justyna Kuska, PhD and Anna Konstantinou dive into the current status of mRNA in therapies and vaccines, explore the manufacturing processes, and shine a light on both its incredible achievements and the challenges that still lie ahead. Read it here: https://lnkd.in/eqx2TuKm

Biosimilar development a real game changer, Biosimilar development has indeed been considered a game changer in the pharmaceutical industry. Biosimilars are biological products that are highly similar to and have no clinically meaningful differences from existing approved reference biologics. Unlike generic versions of small-molecule drugs, which are identical copies of their brand-name counterparts, biosimilars are not exact replicas of the reference biologics due to the complexity of biological molecules. Here are some ways in which biosimilar development is considered a game changer: Cost Savings: Biosimilars offer the potential for significant cost savings compared to their reference biologics. The development of biosimilars can lead to increased competition, reducing the overall cost of biologic drugs and making them more accessible to a larger patient population. Increased Access to Biologic Therapies: Biologic drugs have revolutionized the treatment of various diseases, including cancer, autoimmune disorders, and chronic conditions. Biosimilars provide an opportunity to expand patient access to these life-saving treatments by offering more affordable alternatives. Market Competition: The introduction of biosimilars fosters competition in the biopharmaceutical market. Increased competition can drive innovation, improve product quality, and lead to more competitive pricing, benefitting both patients and healthcare systems. Expanding Treatment Options: Biosimilars can provide healthcare providers and patients with additional treatment options. This can be particularly important when the reference biologic is expensive or in short supply. Healthcare System Sustainability: As healthcare costs continue to rise, biosimilars can contribute to the sustainability of healthcare systems by offering cost-effective alternatives without compromising on the efficacy and safety of treatments. Global Impact: Biosimilar development has a global impact, as it can address healthcare challenges in both developed and developing countries. Increased affordability and accessibility to biologics can improve health outcomes on a global scale. Despite these advantages, biosimilar development also faces challenges, including regulatory hurdles, manufacturing complexities, and concerns about interchangeability with the reference biologics. However, as regulatory frameworks continue to evolve and confidence in biosimilars grows, their role in healthcare is expected to expand. It's important to note that the impact of biosimilar development may vary across different regions and therapeutic areas, and ongoing research and developments will continue to shape the landscape of biosimilars in the pharmaceutical industry. Hence for any of the Pharmaceutical companies looking for development and commercializing of their biosimilar molecules and in urge to fast track your developments from lab to markets , connect with us at imbaig@shilpabio.com & bd_bio@shilpabio.com

Sanofi Pfizer AstraZeneca Pledge Nearly $2.16B in Total Investments in #France Ahead of the French government’s annual Choose France economic summit, several pharmaceutical industry leaders have announced plans to pump a total of approximately $2.16 billion (€2 billion) in investments in the country, according to media reports. Sanofi on Monday announced that it would invest more than $1.08 billion (€1 billion) to boost its biomanufacturing capacity and improve France’s ability to “control the production of essential medicines,” according to its announcement. The investment follows a previous nearly $2.7 billion (€2 billion) commitment by the company in France “to support health sovereignty.” The bulk of the additional funding will go to the company’s site in Vitry-sur-Seine and will help construct a new facility to double the production of monoclonal antibodies at the location. The Vitry site will also potentially help Sanofi manufacture several biologic pipeline assets, including potential blockbusters for asthma, type 1 diabetes and multiple sclerosis. A smaller portion of Monday’s funding will go to Sanofi’s sites at Le Trait and Lyon Gerland, also to expand manufacturing capacity. Overall, the pharma expects its investment to create more than 500 new jobs. CEO Paul Hudson in a statement said that Sanofi has a “record number” of investigational medicines and vaccines with best-in-class potential, which could help the company respond to public health challenges. “With these unprecedented industrial investments, we remain true to our history by once again choosing France to produce these future medicines,” Hudson added. https://lnkd.in/eHwWjHgy

I'm excited to share my latest piece on mRNA-based vaccines and therapeutics. In this article, I explore the current status and future prospects of mRNA technology, delving into how we've reached this pivotal point in medical science. Check it out!

Sanofi reports that it has invested more than €1 billion ($1.1 billion) in Bioproduction in France across 3 sites! The new investment is expected to create more than 500 jobs and strengthen France’s ability to control the production of essential medicines from start to finish, currently and into the future, according to the company. The company will invest €1 billion to build a new facility in Vitry-sur-Seine that will double the site’s monoclonal antibody production capacity. Several biologics in development, including those for chronic obstructive pulmonary disorder (COPD), asthma, multiple sclerosis, and type 1 diabetes, could be produced in Vitry. At the Le Trait site in Normandy, Sanofi will invest €100 million ($109 million) to develop new capacity for biologics formulation, filling, device assembly and packaging. It will support the launch of future biologics and vaccines, as well as for the growth of Dupixent®, which already is indicated in several inflammatory diseases and could soon become the first biologic indicated in COPD, notes a Sanofi official. In Lyon Gerland, Sanofi is investing €10 million ($10.9 million) to locate the production of TZield® in France. Tzield is a biologic for type 1 diabetes that Sanofi acquired in April 2023 and which has been manufactured outside Europe. This plan brings to more than €3.5 billion ($3.8 billion) the amount committed by Sanofi since the COVID-19 pandemic in major projects to keep production of medicines and vaccines in France.

Pharmaceutical company AstraZeneca has set an ambitious target to increase its total revenue to $80 billion by 2030, a 75% rise from $45.8 billion in 2023. This growth will be driven by a robust pipeline focusing on oncology, biopharmaceuticals, and rare diseases, with plans to release 20 new medicines over the next six years. AstraZeneca's Chief Financial Officer, Aradhana Sarin, expressed confidence in achieving this goal, highlighting the potential for many of these new drugs to generate $5 billion annually at their peak. The announcement has already positively impacted AstraZeneca's stock, with shares rising 0.66% following the news. AstraZeneca's strategic focus includes developing treatments for a wide range of cancers and creating alternatives to traditional therapies like chemotherapy and radiation. Additionally, AstraZeneca is investing in advanced manufacturing capabilities, including a new antibody-drug conjugate facility in Singapore, to support the production of these innovative therapies. This investment underscores the company's commitment to leveraging cutting-edge technology to transform cancer treatment. In the post-COVID era, AstraZeneca is shifting its focus back to its core areas of expertise, such as oncology and cardiovascular health, while also exploring new opportunities in diabetes and metabolic diseases. The company is entering the competitive weight management market, aiming to develop drugs that address both weight loss and related comorbidities. This strategic pivot follows the decision to withdraw its COVID-19 vaccine, Vaxzevria, due to declining demand and the availability of newer vaccines. AstraZeneca's continued investment in innovation and strategic acquisitions, such as Fusion Pharmaceuticals, positions it well for sustained growth and leadership in the pharmaceutical industry. #ASpireLifeSciences #astrazeneca #drugdiscovery #pharma #pharmaceuticals https://lnkd.in/eiV6SiZ6

Immuno-Oncology ‘SC Formulations’ Attract Korean Biotech Interest Global pharmaceutical companies are increasingly focusing on developing subcutaneous (SC) formulations of immuno-oncology drugs, a rising trend in the industry. Korean immuno-oncology drug developers are also embracing this challenge, aiming to enhance patient convenience and treatment efficacy. Traditionally, anticancer drugs are administered via intravenous (IV) injections in hospitals, requiring patients to endure infusions lasting at least an hour. In contrast, SC formulations can be self-administered at home in under 10 minutes, significantly improving patient convenience. Industry experts agree that developing SC formulations for immuno-oncology drugs is an unstoppable global trend. In February, Merck (MSD) signed an exclusive agreement with Alteogen to develop an SC formulation of Keytruda (pembrolizumab), the world’s top-selling immuno-oncology drug. With Keytruda’s U.S. and European patents expiring in 2028, MSD is proactively developing the SC formulation to extend its market presence. Alteogen granted MSD worldwide exclusive rights to ALT-B4, a human recombinant hyaluronidase enzyme, to develop and commercialize the SC formulation of Keytruda.